Webinar: The Pros and Cons of Warfarin versus New Oral Anticoagulants (NOACs)

[pala208 2]

The Pros and Cons of Warfarin versus New Oral Anticoagulants (NOAC's)
Wednesday, April 7, 2021, 7 p.m. – 8 p.m. EDT
Presenter: David Gregg, MD

About the Webinar

Some adult patients with congenital heart disease (CHD) take anticoagulants or blood thinners. Do you know why you might need this type of medicine? Do you want to learn more about warfarin and NOACs? Have you wondered how these drugs work and what drug interactions they might have? This webinar will explore what we know about the newer anticoagulants in CHD. It will also discuss the difference in anticoagulants and antiplatelet drugs. Register today so you don’t miss this webinar.

This webinar is made possible in part by an unrestricted educational grant from Janssen, Inc. Pharmaceutical Companies of Johnson & Johnson.

REGISTER NOW: https://bit.ly/2NlMNnX

About the Presenter

David Gregg, MD, serves on the Medical Advisory Board of the Adult Congenital Heart Association. He is the director of the Adult Congenital Heart Disease (ACHD) Program at the Medical University of South Carolina and the director of the Adult Echocardiography lab. He publishes and lectures regularly on imaging in ACHD and multimodality imaging and is excited to talk with you about warfarin and new oral anticoagulants.

About the Adult Congenital Heart Association

The Adult Congenital Heart Association (ACHA) is a national not-for-profit organization dedicated to improving the quality of life and extending the lives of adults with congenital heart disease (CHD). ACHA serves and supports the more than one million adults with CHD, their families and the medical community—working with them to address the unmet needs of the long-term survivors of congenital heart defects through education, outreach, advocacy, and research. For more information about ACHA, contact (888) 921-ACHA or visit www.achaheart.org.

FlyerWarfarinvsNOACsFinalTS.pdf